Circassia Pharmaceuticals plc announced top-line results from its investigational cat allergy immunotherapy phase III study. In the study, both treatment...
Results of a Phase II clinical study show that a course of just four doses of ToleroMune Cat Allergy therapy...
AstraZeneca and MedImmune presented results from the Phase III 1053 clinical trial that evaluated CAT 8015 (moxetumomab pasudotox) in 80...
Purpose: Anticancer agents are known to increase cancer-associated thrombosis (CAT) onset. CAT onset rate is reported to be 1.92% in cisplatin-based therapy, 6.1% in paclitaxel plus ramucirumab combination therapy, and 11.9% in bevacizumab monotherapy.
LEO Pharma announced that CAT 354 (tralokinumab) met all primary and secondary endpoints in its three pivotal Phase III studies...